Abstract:Background Despite the important breakthroughs of immune checkpoint blockade (ICB) therapy in multiple primary cancers, responses of ICB therapy in bone metastases remain extremely poor, largely due to the highly immunosuppressive bone metastasis microenvironment. Tumor-associated neutrophils have recently been reported to have critical impact in the responses of cancer immunotherapies. However, the role of neutrophils within bone metastasis microenvironment is still unknown. Here, we aim to explore the impact of immature neutrophils druing bone metastasis progression, and assess immunotherapies targeting neutrophils to improve ICB therapy in bone metastases. Methods RNA-seq and mass-spectrum data of bone metastasis samples from publicly available databases and our center were obtained. Mouse bone metastasis models from gastric, breast and lung cancer were established, and in vivo treatment efficacy of DKK1 and/or PD-1 blockade was evaluated by micro-computed tomography (CT), micro-magnetic resonance imaging (MRI) and immunohistochemistry (IHC) staining. Impacts of DKK1 on the bone-tumor microenvironment were explored via in vivo immune analysis. The impact of DKK1 on the maturation, function and phenotype of neutrophils was analyzed via in vitro co-culture models. Results The proportion of neutrophils within bone metastasis microenvironment of breast cancer model was gradually increased, and neutrophils gradually became immature (Ly6Ghigh, CD101-, CXCR2-, CXCR4+) during bone metastasis progression, with immature neutrophils occupied the most proportion (80%) at day 14. Meanwhile, analysis of bone metastasis samples from patients identified that DKK1 expression was significantly up-regulated in both mRNA and protein levels. DKK1 directly induced neutrophils to become immature in vitro, and immature neutrophils induced by DKK1 exhibited strong immunosuppressive capacity to inhibit the tumor-killing ability of CD8+ T cells in vitro co-culture models. Next, using multiple bone metastasis mouse models, we observed that DKK1 blockade with murine DKK1 antibody (mDKN-01) significantly controlled the tumor burden of bone metastases and alleviated bone destruction. Results of flow cytometry and immunofluorescence staining on bone metastasis samples demonstrated immature neutrophils were effectively reversed, and both innate and adaptive anti-tumor immunity were improved after DKK1 blockade. Finally, reversion of immature neutrophils by DKK1 blockade remarkedly enhanced the efficacy of PD-1 blockade in bone metastases, and complete response (CR) was observed with combined blockade of DKK1 and PD-1. Conclusions Our study provides novel insights into the critical impact of the immature neutrophils in the immunosuppressive bone metastasis microenvironment. DKK1 is a potential immunotherapeutic target for bone metastases, and dual blockade of DKK1 and PD-1 is a promising combination immunotherapy strategy for patients with bone metastasis. Ethics Approval Collection and analysis of tumor samples were approved by the Ethics Committee of Nanjing University Medical School Affiliated Drum Tower Hospital (2021–324-01). All animal experiments were approved by the Institutional Animal Care and Use Committee of Drum Tower Hospital (2020AE01064). Consent Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

ASK1 suppresses NK cell‐mediated intravascular tumor cell clearance in lung metastasis

Activated Mouse CD4+Foxp3- T Cells Facilitate Melanoma Metastasis Via Qa-1-dependent Suppression of NK Cell Cytotoxicity (127.17)

ASK1 inhibits proliferation and migration of lung cancer cells via inactivating TAZ

Enhanced Anti-Tumor Response Upon Deficiency of Msn Kinase MINK1 in Mice

Metastatic Single Tumor Cells Evade NK Cell-mediated Killing by Thrombin-mediated Loss of the Activating Ligand CD155/PVR/Necl-5

Interplay Of Mkp-1 And Nrf2 Drives Tumor Growth And Drug Resistance In Non-Small Cell Lung Cancer

Inactivation of ABL kinases suppresses non-small cell lung cancer metastasis.

ASK1 inhibition reduces cell death and hepatic fibrosis in an Nlrp3 mutant liver injury model

Inhibition of ASAP1 Modulates the Tumor Immune Microenvironment and Suppresses Lung Cancer Metastasis via the p-STAT3 Signaling Pathway

Metastasis-associated macrophages constrain antitumor capability of natural killer cells in the metastatic site at least partially by membrane bound transforming growth factor β

STK11 mutation affects the killing effect of NK cells to promote the progression of lung adenocarcinoma

971 Immature Neutrophils Inhibit Anti-Tumor Immunity and Impede Checkpoint Blockade Therapy in Bone Metastases

ASK1 Is Essential for JNK/SAPK Activation by TRAF2

Primary Tumors Limit Metastasis Formation through Induction of IL15-Mediated Cross-Talk between Patrolling Monocytes and NK Cells

HPK1 Dysregulation‐Associated NK Cell Dysfunction and Defective Expansion Promotes Metastatic Melanoma Progression

Functional visualization of NK Cell-mediated killing of metastatic single tumor cells

Tumor‐associated macrophages promote the metastasis and growth of non‐small‐cell lung cancer cells through NF‐κB/PP2Ac‐positive feedback loop

Harnessing NK Cells to Control Metastasis

Syngeneic natural killer cell therapy activates dendritic and T cells in metastatic lungs and effectively treats low-burden metastases

Abstract 3925: Cancer-associated fibroblast-derived Dickkopf-1 impairs anti-tumor immunity in breast cancer by suppressing NK cell-mediated cytotoxicity

Resting natural killer cells promote the progress of colon cancer liver metastasis by elevating tumor-derived sSCF